MondayNightIBD ~ IL-23s in IBD Tweetorial
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, complete the post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

1. What are your specialty & credentials? (Required.)

IBD Specialist

General GI

Colorectal Surgeon

Fellow/Trainee

APP

Nurse

PharmD

Other (please specify)

Question Title

2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

3. 25 y/o with new diagnosis of Crohns colitis was started on UST, without response, FCP 450. The patient asks if the new drugs he has seen on TV are an option. You explain there is data that show that in patient with no response to UST (IL12/IL23)? (Required.)

IL23 are not effective

IL23 can worsen inflammation

IL23 can be effective

Question Title

4. In LUCENT trials, patients with UC with no response to the 3 IV MIRI induction doses and who received an extended induction (3 more MIRI IV doses) , achieved the following clinical response and clinical remission at week 52 (whether bio-naive or exposed) (Required.)

50% and 15%

60% and 25%

70% and 35%

EVALUATION FORM

Question Title

5. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD	Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Strongly agree	Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Agree	Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Disagree	Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Strongly disagree

Question Title

6. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree

Question Title

7. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

8. If no, please explain:

Question Title

9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

10. Based on what I learned today, I will improve my practice by incorporating the following for my patients with IBD (check all that apply):

Consider anti-IL23p19 therapies for patients

Utilize the latest efficacy data to make evidence-based decisions when selecting between IL-23 therapies

Individualize treatment selection for patients with UC and Crohn's

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding anti-IL23p19 subunits (provider-related barrier)

Challenges applying frequency and quantity of new data into practice (provider-related barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Limited access to novel therapies (systems-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Other (please specify)

Question Title

12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information. (Required.)

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IL-23p19 agents in IBD Tweetorial" and claim 0.5 AMA PRA Category 1 Credit^TM. (Required.)

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

MondayNightIBD ~ IL-23s in IBD Tweetorial***Post-Survey & Application for CME Credit***

Question Title

* 1. What are your specialty & credentials? (Required.)

Question Title

* 2. What is your community of practice?

Question Title

* 3. 25 y/o with new diagnosis of Crohns colitis was started on UST, without response, FCP 450. The patient asks if the new drugs he has seen on TV are an option. You explain there is data that show that in patient with no response to UST (IL12/IL23)? (Required.)

Question Title

* 4. In LUCENT trials, patients with UC with no response to the 3 IV MIRI induction doses and who received an extended induction (3 more MIRI IV doses) , achieved the following clinical response and clinical remission at week 52 (whether bio-naive or exposed) (Required.)

Question Title

* 5. Upon completion of this activity, I am able to:

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following for my patients with IBD (check all that apply):

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 12. For purposes of certification, you must complete the following information. *Please note that we will not forward or sell your contact information.* (Required.)

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IL-23p19 agents in IBD Tweetorial" and claim 0.5 AMA PRA Category 1 CreditTM. (Required.)

MondayNightIBD ~ IL-23s in IBD Tweetorial
Post-Survey & Application for CME Credit

1. What are your specialty & credentials? (Required.)

2. What is your community of practice?

3. 25 y/o with new diagnosis of Crohns colitis was started on UST, without response, FCP 450. The patient asks if the new drugs he has seen on TV are an option. You explain there is data that show that in patient with no response to UST (IL12/IL23)? (Required.)

4. In LUCENT trials, patients with UC with no response to the 3 IV MIRI induction doses and who received an extended induction (3 more MIRI IV doses) , achieved the following clinical response and clinical remission at week 52 (whether bio-naive or exposed) (Required.)

5. Upon completion of this activity, I am able to:

6. Please indicate the extent of your agreement with the following statements:

7. Overall, was this activity fair, balanced and free from commercial bias?

8. If no, please explain:

9. Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

10. Based on what I learned today, I will improve my practice by incorporating the following for my patients with IBD (check all that apply):

11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

12. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information. (Required.)

13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IL-23p19 agents in IBD Tweetorial" and claim 0.5 AMA PRA Category 1 Credit^TM. (Required.)